The newest treatments for myasthenia gravis (MG) approved in 2023 are rozanolixizumab-noli (Rystiggo) and zilucoplan (Zilbrysq).
Details on the New Treatments
These medications represent advances in MG therapy, offering new options for patients with specific types of the disease.
-
Rozanolixizumab-noli (Rystiggo): This medication is approved for treating adults with generalized myasthenia gravis (gMG) who are anti–acetylcholine receptor (AChR) antibody-positive or anti–muscle-specific kinase (MuSK) antibody-positive. It is the first treatment approved for both of these antibody subtypes.
-
Zilucoplan (Zilbrysq): This is the first self-administered subcutaneous (under the skin) injection treatment approved for generalized myasthenia gravis. It is given daily.
Significance of these Approvals
The approval of rozanolixizumab-noli and zilucoplan provides patients with MG and their healthcare providers more treatment options tailored to specific disease characteristics. These advancements can lead to better disease management and improved quality of life.
